Overall, these data suggest that the effect of miR-16 on NSCLC cell primary resistance to erlotinib is, at least in part, mediated by its direct targeting of MAPK3 and MAP2K1 but not of CRAF. The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.